Evidence map›Paper›PMID 40255869›Full record

ArticleKidney diseases (Basel, Switzerland)

Sacubitril-Valsartan Lowers Blood Pressure in Patients on Dialysis: A Randomized Controlled Multicenter Study.

Li Lin, Weijing Bian, Qun Luo, Liang Wang, Na Liu, Min Yang, Jun Cen, Kedan Cai, Jia Hua, Hongwei Gu and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Kidney diseases (Basel, Switzerland). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Li LinDepartment of Nephrology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Weijing BianDepartment of Nephrology, Beijing Anzhen Hospital Affiliated to Capital Medical University, Beijing, China.
Qun LuoDepartment of Nephrology, Ningbo Huamei Hospital, University of Chinese Academy of Sciences, Ningbo, China.
Liang WangDepartment of Nephrology, People's Hospital of Wuxi City, Wuxi, China.
Na LiuDepartment of Nephrology, Oriental Hospital of Tongji University, Shanghai, China.
Min YangDepartment of Nephrology, Beijing Anzhen Hospital Affiliated to Capital Medical University, Beijing, China.
Jun CenDepartment of Nephrology, Shanghai Construction Group Hospital, Shanghai, China.
Kedan CaiDepartment of Nephrology, Ningbo Huamei Hospital, University of Chinese Academy of Sciences, Ningbo, China.
Jia HuaDepartment of Nephrology, People's Hospital of Wuxi City, Wuxi, China.
Hongwei GuDepartment of Nephrology, Oriental Hospital of Tongji University, Shanghai, China.
Hualin QiDepartment of Nephrology, Shanghai Pudong New Area People's Hospital, Shanghai, China.
Zhihong WangDepartment of Nephrology, Shanghai Pudong New Area People's Hospital, Shanghai, China.
Jianying NiuDepartment of Nephrology, The Fifth People's Hospital of Shanghai, Fudan University, Shanghai, China.
Yu ChenDepartment of Nephrology, The Fifth People's Hospital of Shanghai, Fudan University, Shanghai, China.
Yizheng GuDepartment of Nephrology, Shanghai Construction Group Hospital, Shanghai, China.
Chun HuDepartment of Nephrology, The Ninth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Suhua LiDepartment of Nephrology, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.
Yan LiDepartment of Cardiovascular Medicine, Shanghai Institute of Hypertension, Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China.
Nan ChenDepartment of Nephrology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Xiao LiDepartment of Nephrology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Individuals with end-stage kidney disease frequently grapple with uncontrolled hypertension, which elevates their risk for cardiovascular complications. Methods: This randomized, controlled, multicenter study, conducted across 10 hospitals, aimed to compare the effectiveness and safety of sacubitril-valsartan versus irbesartan in managing hypertension among dialysis patients. The primary efficacy variable of the present study was the reduction in office blood pressure (BP) after 12 months of treatment. Participants were randomly allocated to receive either sacubitril-valsartan (angiotensin receptor-neprilysin inhibitor [ARNI]) or irbesartan (angiotensin receptor blocker [ARB]) treatment over a 12-month period. We gauged treatment efficacy through office and 24-h ambulatory BP readings, as well as serum concentrations of N-terminal pro-brain natriuretic peptide (NT-proBNP). Safety outcomes were also evaluated. Results: Baseline office BP averaged 150/82 mm Hg and median NT-proBNP was 6,336 pg/mL. In the intention-to-treat analysis, office systolic BP reduction was significantly greater in the ARNI than ARB group (-10.4 vs. -4.6 mm Hg, Conclusion: In dialysis patients with hypertension, especially those undergoing HD, ARNI demonstrated superior effectiveness in reducing BP compared to ARB. The safety profiles of both treatments were comparable and acceptable.

Indexed as

Angiotensin receptor-neprilysin inhibitorClinical trialDialysis patientsHypertensionSacubitril-valsartan

Identifiers

PMID40255869
PMCPMC12007916

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.